ArriVent BioPharma SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 26, 2026, 6 a.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedArriVent BioPharma (AVBP) Reports 44.8% ORR at 6 mg/kg in Late-Line CRC for Phase 1 ARR-217 ADC
8-KOct. 19, 2026, 8:08 a.m. ETView on SEC.gov
Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedArriVent BioPharma Publishes FURTHER Phase 1b Firmonertinib Data in Cancer Cell, Reporting 43% and 68% Confirmed ORR in EGFR PACC-Mutant NSCLC
SCHEDULE 13GOct. 13, 2026, 4:01 p.m. ETView on SEC.gov
8-KOct. 13, 2026, 6:03 a.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits
SCHEDULE 13D/AOct. 8, 2026, 6:39 p.m. ETView on SEC.gov
8-KOct. 6, 2026, 8:07 a.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits
10-QAug. 12, 2026, 4:20 p.m. ETView on SEC.gov
8-KAug. 12, 2026, 4:07 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Results of operations and financial condition · Financial statements and exhibits
SCHEDULE 13G/AJuly 27, 2026, 4:25 p.m. ETView on SEC.gov